Identification of distinct phenotypes related to benralizumab responsiveness in patients with severe eosinophilic asthma.

ABSTRACT:

Purpose

To characterize the clinical phenotypes of severe eosinophilic asthma based on early responsiveness to benralizumab in terms of forced expiratory volume in 1 second (FEV1) improvement.

Patients and methods

Sixty-four participants diagnosed with severe eosinophilic asthma and who had completed 4 months of benralizumab treatment were included in this analysis. Pre-treatment clinical factors were compared between responders and non-responders according to improvements in ACT or FEV1. Correlations between the sums of increased Type 2-related inflammatory parameters and changes of ACT or FEV1 were also evaluated before and after the 4-month treatment. A two-step cluster analysis was performed to identify distinct phenotypes related to benralizumab responsiveness in terms

SUBMITTER: Yamada H 

PROVIDER: S-EPMC7951858 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature